A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: BIOLOGICAL: Aldesleukin|BIOLOGICAL: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Mammogram|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Ultrasound Imaging
Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)